secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxxinity, Inc. (—)
CIK:        0001851657
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001562762-23-000295
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 4.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxxinity auditor Armanino resigns; appoints Peter Powchik as EVP Global Scientific Director
--------------------------------------------------------------------------------

- Armanino LLP resigns as auditor effective upon new appointment or Q3 2023 filing; cites transition away from public company audits.
- No disagreements or reportable events in past two fiscal years and subsequent interim period.
- Company warns inability to timely replace auditor could impair SEC filings, capital raising, and investor confidence.
- Peter Powchik, M.D. appointed EVP, Global Scientific Director effective Oct 1, 2023; previously led development of seven approved drugs at Regeneron.
- Ulo Palm transitions from CMO to senior advisor effective Oct 1, 2023; oversaw Phase 3 COVID-19 and Phase 1 Parkinson's trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851657/000156276223000295/0001562762-23-000295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851657/000156276223000295/20230726_8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-23-000295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer